Louisiana chucks Risperdal settlement

Share this article:

A Louisiana appeals court has overturned a Risperdal settlement to Johnson & Johnson's advantage. Bloomberg reports that the court tossed a $257.7 million deceptive marketing verdict, saying prosecutors failed to provide enough evidence of wrongdoing.

Despite the local win for J&J, Louisiana is just a minor point in a bigger marketing tangle, which includes allegations from the Department of Justice that the drugmaker's marketing strategies triggered fraudulent government payments for the anti-psychotic, and allegations of tying speaker fees to prescription rates, among others.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.